News

Terms of the acquisition were not disclosed, but include an investment in TrialScope by its investors of $5 million for technology development, sales and marketing in addition to

"I am pleased that our team has achieved this very important milestone, which also further strengthens our financial position," said Nancy Pecota, Chief Financial Officer, Aradigm. The Phase

The focus of the collaboration is the development of an effective therapy for GA using Foamix’s stable patented topical OilGel formulation containing minocycline, an antibiotic in the tetracycline

Using Medrio’s eClinical Software as a Service (SaaS) suite, bioskin is able to provide clients a user-friendly, efficient and cost-effective solution for data collection. "Our data managers are

The expansion includes significant incremental capacity to existing services, and will also provide Frontage with additional room for future growth. The renovation plan involves two phases. Initial enhancements,

Since 2007, BMS has been working with Syngene and its corporate parent, Biocon, to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and

AZD0914 is a novel oral antibiotic entering Phase II clinical trials to investigate efficacy in treating uncomplicated gonorrhoea and is the first of a novel class of molecules

The company expects lab results, pharmacokinetic studies, and analysis to take about two months. If the results shows bioequivalence of Prurisol with Abacavir Sulfate, Cellceutix will then schedule

Additionally, the company had recently received a Notice of Allowance from the US Patent & Trademark Office for its Emesyl trademark. The NDC number and trademark Notice of